Document is current
Any future updates will be listed below
-
Authors
Song, Mengmeng
Scheifele, Maximilian
Barthel, Henryk
van Eimeren, Thilo
Beyer, Leonie
Marek, Ken
Eckenweber, Florian
Palleis, Carla
Kaiser, Lena
Finze, Anika
Kern, Maike
Nitschmann, Alexander
Biechele, Gloria
Katzdobler, Sabrina
Bischof, Gèrard
Hammes, Jochen
Jessen, Frank
Saur, Dorothee
Schroeter, Matthias L.
Rumpf, Jost-Julian
Rullmann, Michael
Schildan, Andreas
Patt, Marianne
Neumaier, Bernd
Stephens, Andrew W.
Rauchmann, Boris-Stephan
Perneczky, Robert
Levin, Johannes
Classen, Joseph
Höglinger, Günter U.
Bartenstein, Peter
Boening, Guido
Ziegler, Sibylle
Villemagne, Victor
Drzezga, Alexander
Seibyl, John
Sabri, Osama
Brendel, Matthias http://orcid.org/0000-0002-9247-2843
,
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (EXC 2145 SyNergy – ID 390857198)
- License Information
-
More Information
Article History
Received: 24 January 2021
Accepted: 26 April 2021
First Online: 22 May 2021
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (LMU Munich—approval numbers 17-569 and 19-022) and with the 1964 Helsinki declaration and its later amendments.
: Informed consent was obtained from all patients.
: M.B. received speaker honoraria from GE healthcare and LMI and is an advisor of LMI. M.T.B. received speaker’s honoraria from Medtronic, Boston Scientific, Abbott (formerly St. Jude), GE Medical, UCB, Bial and research funding from the Felgenhauer-Stiftung, Forschungspool Klinische Studien (University of Cologne), H2020, Medtronic and Boston Scientific. C.P. received research funding from Lüneburg heritage. G.U.H. received research support from GE Healthcare and Neuropore; has ongoing research collaborations with Orion and Prothena; serves as a consultant for AbbVie, AlzProtect, Asceneuron, Biogen, Biohaven, Lundbeck, Novartis, Roche, Sanofi, and UCB; received honoraria for scientific presentations from AbbVie, Biogen, Roche, Teva, UCB, and Zambon; and holds a patent on PERK Activation for the Treatment of Neurodegenerative Diseases (PCT/EP2015/068734). G.R. received honoraria for scientific presentations from Biogen. O.S. receives research support from LMI. All other authors do not report a conflict of interest.
